LISATA THERAP.INC.DL-001 (8NE) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.223x

Based on the latest financial reports, LISATA THERAP.INC.DL-001 (8NE) has a cash flow conversion efficiency ratio of -0.223x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.25 Million ≈ $-3.80 Million USD) by net assets (€14.60 Million ≈ $17.07 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See LISATA THERAP.INC.DL-001 balance sheet independence to measure how much of total assets are equity-financed.

LISATA THERAP.INC.DL-001 - Cash Flow Conversion Efficiency Trend (2021–2025)

This chart illustrates how LISATA THERAP.INC.DL-001's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore LISATA THERAP.INC.DL-001 (8NE) cash flow to debt to assess how comfortably operating cash covers total debt obligations.

LISATA THERAP.INC.DL-001 Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of LISATA THERAP.INC.DL-001 ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
UET United Electronic Technology AG XETRA:CFC	8.013x
Versus Systems Inc NASDAQ:VS	0.120x
Fidelity Emerging Markets Ord LSE:FEML	0.103x
Forum Energy Metals Corp V:FMC	0.046x
Kibo Energy PLC JSE:KBO	-0.011x
Bong AB (publ) ST:BONG	0.104x
Accuracy Shipping Limited NSE:ACCURACY	0.085x
Morgan Advanced Materials plc LSE:MGAM	0.133x

Annual Cash Flow Conversion Efficiency for LISATA THERAP.INC.DL-001 (2021–2025)

The table below shows the annual cash flow conversion efficiency of LISATA THERAP.INC.DL-001 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see 8NE market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€14.60 Million ≈ $17.07 Million	€-15.95 Million ≈ $-18.65 Million	-1.092x	-65.45%
2024-12-31	€29.32 Million ≈ $34.27 Million	€-19.36 Million ≈ $-22.63 Million	-0.660x	-57.85%
2023-12-31	€47.89 Million ≈ $55.99 Million	€-20.03 Million ≈ $-23.42 Million	-0.418x	-31.04%
2022-12-31	€66.32 Million ≈ $77.54 Million	€-21.17 Million ≈ $-24.75 Million	-0.319x	-32.01%
2021-12-31	€92.00 Million ≈ $107.56 Million	€-22.25 Million ≈ $-26.01 Million	-0.242x	--

About LISATA THERAP.INC.DL-001

F:8NE Germany Biotechnology

Market Cap

$7.83 Million

€6.69 Million EUR

Market Cap Rank

#27630 Global

#2381 in Germany

Share Price

€0.74

Change (1 day)

-5.16%

52-Week Range

€0.74 - €4.34

All Time High

€183.30